key: cord-0258539-yg120w7r authors: Willett, B. J.; Grove, J.; MacLean, O.; Wilkie, C.; Logan, N.; De Lorenzo, G.; Furnon, W.; Scott, S.; Manali, M.; Szemiel, A.; Ashraf, S.; Vink, E.; Harvey, W.; Davis, C.; Orton, R.; Hughes, J.; Holland, P.; Silva, S. V.; Pascall, D.; Puxty, K.; da Silva Filipe, A.; Yebra, G.; Shaaban, S.; Holden, M. T. G.; Pinto, R. M.; Gunson, R.; Templeton, K.; Murcia, P.; Patel, A.; The COVID-19 DeplOyed VaccinE Investigators,; COVID-19 EVADE Cohort Study,; The COVID-19 Genomics UK Consortium,; The G2P-UK National Virology Consortium,; Haughney, J.; Robertson, D. L.; Palmarini, M. title: The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism date: 2022-01-03 journal: nan DOI: 10.1101/2022.01.03.21268111 sha: 87e3e2c7749c1ce1333612a1c57b4af0c96a12ea doc_id: 258539 cord_uid: yg120w7r Vaccination-based exposure to spike protein derived from early SARS-CoV-2 sequences is the key public health strategy against COVID-19. Successive waves of SARS-CoV-2 infections have been characterised by the evolution of highly mutated variants that are more transmissible and that partially evade the adaptive immune response. Omicron is the fifth of these Variants of Concern (VOCs) and is characterised by a step change in transmission capability, suggesting significant antigenic and biological change. It is characterised by 45 amino acid substitutions, including 30 changes in the spike protein relative to one of the earliest sequences, Wuhan-Hu-1, of which 15 occur in the receptor-binding domain, an area strongly associated with humoral immune evasion. In this study, we demonstrate both markedly decreased neutralisation in serology assays and real-world vaccine effectiveness in recipients of two doses of vaccine, with efficacy partially recovered by a third mRNA booster dose. We also show that immunity from natural infection (without vaccination) is more protective than two doses of vaccine but inferior to three doses. Finally, we demonstrate fundamental changes in the Omicron entry process in vitro, towards TMPRSS2-independent fusion, representing a major shift in the replication properties of SARS-CoV-2. Overall, these findings underlie rapid global transmission and may alter the clinical severity of disease associated with the Omicron variant. Protection against Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) associated disease is currently reliant on a range of vaccine technologies that induce immunity to the spike protein of the virus that first emerged in Wuhan city, China in 2019. Such early variant vaccines have become the cornerstone of the global public health response to SARS-CoV-2 1 but are threatened by the successive emergence of Variants of Concern (VOC) displaying increased transmissibility and/or evasion of adaptive immunity 2 . The evolution of SARS-CoV-2 variants with high transmission rates, increase the risk of the generation of variants of the virus with novel properties that may compromise this crucial element of the public health response. The balance between transmission advantage and immune evasion has resulted in the evolution of five VOCs that display these characteristics to varying degrees. The Beta (B.1.351 in Pango nomenclature) and, to a lesser extent, Gamma (P.1) variants were associated with immune evasion in vitro and spread locally but never dominated globally. In contrast, the Alpha (B.1.1.7) and Delta (B.1.617.2) VOCs attained a worldwide distribution and were responsible for significant waves of infections associated with an increase in reproduction number (R 0 ). Both variants harbour mutations at position 681 within the polybasic furin cleavage site (a histidine in Alpha and an arginine in Delta); changes associated with enhanced cell entry that likely confer an intrinsic transmission advantage. Alpha displayed lower immune evasion properties compared to Beta but higher transmission. Alpha was in turn replaced by the Delta variant that displayed more significant immune evasion in addition to enhanced furin cleavage [2] [3] [4] [5] . Omicron is the fifth variant to be named as a VOC by the World Health Organisation (WHO) and the third (after Alpha and Delta) to achieve global dominance. The Omicron lineage (B.1.1.529) was first detected in mid-November 2021 in Botswana, South Africa 6 and quarantined travellers in Hong Kong 7 . It has split into three divergent sublineages (BA.1, BA.2 and BA.3) of which BA.1 has spread rapidly around the world. The BA.1 Omicron genome encodes 30 amino acid substitutions relative to Wuhan-Hu-1 within the spike glycoprotein ( Fig.1) , 15 of which are in the receptor-binding domain (RBD) and 9 within the receptor-binding motif (RBM), the RBD subdomain that interacts with the human ACE2 receptor. Six of these mutations (G339D, N440K, S477N, T478K, Q498R and N501Y) enhance binding affinity to the human ACE2 receptor. Combinations such as Q498R and N501Y may enhance ACE2 binding additively 8 . Overall, the Omicron RBD binds to the human ACE2 with approximately double the affinity (x2.4) of the Wuhan RBD 9 . Seven Omicron RBD mutations (K417N, G446S, E484A, Q493R, G496S, Q498R and N501Y) are associated with decreased antibody binding, importantly falling in epitopes corresponding to the three principal classes of RBD-specific neutralising antibodies. 4 Three deletions (amino acids 69-70, 143-145 and 211 ) and an insertion (at site 214) are also present in the amino-terminal domain (NTD) of the Omicron spike glycoprotein. The 69-70 deletion is also found in the Alpha and Eta (B.1.525) variants and is associated with enhanced fusogenicity and incorporation of cleaved spike into virions 10 . This deletion can also be used as a useful proxy for prevalence estimates in the population by S-gene target failure (SGTF) using the TaqPath TM (Applied Biosystems, Pleasanton, CA) diagnostic assay. Deletions in the vicinity of amino acids 143-145 have been shown to affect a range of NTD-specific neutralising antibodies 11, 12 . Two mutations (N679K and P681H) at the S1/S2 furin cleavage site (FCS), have individually been found to enhance furin cleavage in other variants, contributing to enhanced infectivity, while a third (H655Y, also present in the Gamma VOC) occurs in the vicinity of the FCS 13 . The role of these changes in combination requires further investigation. Several mutations, such as the deletion at site 211, are not present at high frequency in other VOCs in the global sequencing data, suggesting historic negative selection 14 . Outside the spike protein, 15 amino acid substitutions are present and require further characterisation. For example, a deletion within NSP6 (105-107) may contribute to immune evasion through virus-induced cellular autophagy 15 . Critically, emerging data indicate that the Omicron variant evades neutralisation by sera obtained from people vaccinated with 1 or 2 doses of vaccine, especially when antibody titres are waning. Indicative studies have shown that 3 doses of Wuhan-strain based vaccines may provide only partial protection from infection with this variant, including unpublished data made available as a press release from Pfizer. Immune evasion by Omicron may have contributed to the extremely high transmission rates in countries with high vaccination rates or natural immunity (R 0 of 3-5 in the UK) 9, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . In this study, we aimed to investigate the antigenic and biological properties of the Omicron variant that might underly immune evasion and increased transmission of the virus. We demonstrate that vaccine effectiveness is significantly reduced against the Omicron variant in association with neutralising antibody responses from dual and triple recipients of the BNT162b2 (Pfizer), ChAdOx1 (Astra Zeneca) and mRNA-1273 (Moderna) COVID-19 vaccines. Further, using live virus culture and viral pseudotypes, we describe an altered entry pathway that favours endosomal fusion over the TMPRSS2-dependent, cell surface fusion utilised by all previous variants of SARS-CoV-2. In summary, Omicron exhibits significant antigenic and biological changes that underpin immune evasion and hyper-transmissibility and could affect the pathogenesis and clinical severity of disease. The Omicron variant is characterised by significant changes within the RBD of the spike glycoprotein, regions targeted by class 1,2 and 3 RBD-directed antibodies, and within the NTD supersite (Fig.1A) . Deep mutational scanning (DMS) estimates at mutated sites are predictive of substantially reduced monoclonal and polyclonal antibody binding and altered binding to human ACE2 (Fig.1B) 26 . Fourteen mutations (K417N, G446S, E484A, Q493R, G496S, Q498R and to a lesser extent, G339D, S371L, S373P, N440K, S477N, T478K, N501Y and Y505H) may be predicted to evade antibody binding based on a calculated escape fraction (a quantitative measure of the extent to which a mutation reduces polyclonal antibody binding by DMS). Seven Omicron RBD mutations (K417N, G446S, E484A, Q493R, G496S, Q498R and N501Y) have been shown previously to be associated with decreased antibody binding, importantly falling in epitopes corresponding to three major classes of RBD-specific neutralising antibodies. The mutations present in spike also involve key structural epitopes targeted by several monoclonal antibodies in current clinical use. Of these, seven bind to the RBM (bamlanivimab, cilgavimab, casirivimab, etesevimab, imdevimab, regdanvimab and tixagevimab) and neutralisation of Omicron has been shown to be negligible or absent. An eighth mAb, sotrovimab, targets a conserved epitope common to SARS-CoV-1 and SARS-CoV-2 outside the RBM and has only a small reduction (x3) in neutralisation potency [27] [28] [29] . Two mutations at the furin cleavage site (N679K and P681H) are individually predicted to increase furin cleavage, although the combination of these changes and an adjacent change with unknown function (H655Y, also present in the Gamma VOC) is unknown. Despite high vaccination rates and levels of natural immunity following previous exposure in the UK, the Omicron variant has rapidly become dominant. The evolutionary relationships of SARS-CoV-2 variants at a global level are shown in Fig.1C . The first 8 cases of Omicron were detected in the UK on the 27 th and 28 th November 2021 (2 in England and 6 in Scotland). Due to the rapid spread of Omicron, early genome sequences were highly related with an average genetic divergence between 1 and 7 single nucleotide polymorphisms (SNPs) (Fig.1D ). The phylogenetic relationship to Omicron sequences from other countries was consistent with multiple introductions associated with travel to South Africa followed by community transmission (discussed further in Supplementary Information). Within Scotland, 111 cases were detected in the first 10 days of the outbreak, spread across 9 separate Health Boards, the majority in NHS Greater Glasgow & Clyde (NHS GG&C). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint representation. Colouring highlights mutations at residues with substitutions impacting RBD-specific antibodies of classes 1 (green), 2 (yellow), and 3 (blue) 30 , or that belong to the NTD antibody supersite (magenta) 11 , or that belong to the FCS (orange), with the remainder in grey. These are annotated on the monomer with an 'up' receptor-binding domain. The substitution D614G which is shared by common descent by all lineage B.1 descendants is italicised. The visualisation is made using a complete spike model 31 which is in turn based upon a partial cryo-EM structure (RCSB Protein Data Bank (PDB) ID: 6VSB 32 ). (B) Aligned heatmaps showing properties of amino acid residues or of the specific amino acid substitution present in the Omicron variant, as appropriate (insertion not shown). Structure-based epitope scores 33 for residues in the structure of the original genotype spike in closed and open conformations are shown. For RBD residues, the results of deep mutational scanning (DMS) studies show the escape fraction (that is, a quantitative measure of the extent to which a mutation reduced polyclonal antibody binding) for each mutant averaged across plasma ('plasma average') and for the most sensitive plasma ('plasma max') 26 . Each mutation is classified as having evidence for mutations affecting neutralisation by either mAbs) 11, 12, [34] [35] [36] Neutralising responses to Omicron (BA.1) are substantially reduced following double and partially restored following triple vaccination Levels of neutralising antibodies in patient sera correlate strongly with protection from infection [40] [41] [42] [43] , and reductions in neutralising activity against the Alpha and Delta variants are consistent with an observed reduction in vaccine effectiveness [2] [3] [4] [5] 44 . To investigate the likely effect of the mutations in the Omicron spike glycoprotein on vaccine effectiveness, sera collected from healthy volunteers at more than 14 days post-2 nd dose vaccination with either BNT162b2, ChAdOx1 or mRNA-1273 were sorted into three age-matched groups (n=24 per group, mean age 45 years). Sera were first screened by electrochemiluminescence (MSD-ECL) assay for reactivity with SARS-CoV-2 antigens (Spike, RBD, NTD or nucleoprotein (N)). The antibody responses to RBD and NTD were significantly higher (p<0.0001) in the sera from individuals vaccinated with BNT162b2 or mRNA-1273 in comparison with the ChAdOx1 vaccinees ( Fig. 2A , Supp. Table S1 ). In contrast, antibody responses to endemic human coronaviruses (HCoVs) (Supp. Fig. S1 , Supp. Table S2 ) or influenza (Supp. Fig. S2 , Supp. Table S3) were . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. Next, the neutralising antibody responses against SARS-CoV-2 pseudotypes expressing the spike glycoprotein from either Wuhan-Hu-1, or Omicron (BA.1) were compared (Fig. 3B) . Vaccination with mRNA-1273 elicited the highest neutralising antibody titres (mean titre Wuhan=21,118, Omicron=285), in comparison with those elicited by vaccination with either BNT162b2 (Wuhan=4978, Omicron=148.3) or ChAdOx1 (Wuhan=882.3, Omicron=61.9). Neutralising antibody titres against Wuhan differed significantly between the three study groups. Activity against Omicron was markedly reduced in comparison with Wuhan, reduced by 33-fold for BNT162b2, 14-fold for ChAdOX1 and 74fold for mRNA-1273 (Supp . Table S4 ). While the fold change in neutralisation was lowest in recipients of the ChAdOx1 vaccine and highest in recipients of the mRNA-1273 vaccine, absolute neutralisation values were highest in mRNA-1273 followed by BNT162b2 and ChAdOx1. Neutralisation was lowest in the ChAdOx1 group, however it is important to note that this was given to older patients during early vaccine rollout in the UK, especially to vulnerable patients in nursing homes and was not recommended in young adults less than 40 years. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint (B) Neutralising antibody responses were quantified against Wuhan or Omicron spike glycoprotein bearing HIV(SARS-CoV-2) pseudotypes. Each point represents the mean of three replicates, bar represents the group mean. In panel B, % neutralising refers to the % of serum samples that displayed neutralising activity. Next, samples were analysed from vaccine recipients at least 14 days post booster vaccination (third dose). Participants had been primed with two doses of either ChAdOx1 or BNT162b2, followed by a third dose of either BNT162b2 or mRNA-1273 (half dose; 50µg). All sera reacted strongly with SARS-CoV-2 antigens by MSD-ECL, with no significant differences between the four groups (Fig. 3A , Supp. Table S8 ). The marked increase in antibody titre in ChAdOx1-primed individuals (Supp. Fig. S5) emphasises the importance of the third dose booster in this population. Indeed, following boost with either BNT162b2 or mRNA-1273, anti-Wuhan neutralising antibody titres in the ChAdOx1-primed group were not significantly different from those primed with BNT162b2 (Supp . Table S8 ). Neutralising antibody titres against Omicron were lower in both booster study groups and did not differ significantly in titre (Supp . Table S8 ). However, absolute numbers displaying measurable Omicron neutralising activity were higher in the ChAdOx1-primed group (13/21, 62%) compared with the BNT162p2 primed group (5/20, 25%) (Fig. 3B) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. We next used a logistic additive model with a test negative case control design to estimate relative vaccine effectiveness against becoming a confirmed case with Delta (2553 cases) and/or Omicron for Omicron and Delta was modelled by number and product type of vaccine doses, previous infection status, sex, SIMD quartile, and age (to control for demographic bias). We ran two models, one with time since vaccination included, to estimate the protection provided by recent vaccination, and one without, to observe the current protection in today's mixed and waned population. Immunosuppressed individuals were removed from the analysis to ensure case-positivity could be . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint attributed to vaccine escape rather than an inability to mount a vaccine response. Age and time since vaccination were each modelled as single smooth effects using thin plate regression splines 45 . In both models, we estimated the protection from vaccine-acquired and infection-acquired immunity as being markedly reduced against Omicron compared with Delta. Estimates of vaccine effectiveness in recent recipients (at 14 days post-dose) were negative for full primary courses of ChAdOx1 against Omicron and only 16% against Delta. For two doses of mRNA vaccines, vaccine effectiveness was significantly lower for Omicron versus Delta; BNT162b2 (6.84% versus 56.53%) and mRNA-1273 (8.83% versus 60.07%) (Fig.4C ). These responses increased significantly following a third booster dose of BNT162b2 or mRNA-1273 to 91.87% and 89.28% against Delta and 67.57% and 71.15% against Omicron. These estimates are similar to those reported against symptomatic infection recently in England where vaccine effectiveness was estimated as 71.4% and 75.5% for ChAdOx1 and BNT162b2 primary course recipients boosted with BNT162b2, respectively 18 . Our estimates of protection in the current GG&C cohort, whose median time since most recent dose is 5 months, were notably lower (Fig.4D ). This waning of protection was evident for both variants, leading to very low levels of protection against Omicron in double vaccine recipients of ChAdOx1, BNT162b2 and mRNA-1273 (5.19%, 24.39% and 24.86% respectively). Our estimates for current protection against Omicron in recipients of a third booster dose of BNT162b2 or mRNA-1273 were much higher at 59.21% and 64.9%. We next estimated the additive protective effect of previous natural infection. Infection-acquired immunity directed against other VOCs may be broader in nature and may wane more slowly than that induced by vaccines [46] [47] [48] . The level of protection following previous infection was 53.2% for Omicron, and 88.7% for Delta. This level of protection was greater than two doses of vaccine but did not reach levels attained by those who had never had natural infection and had received third dose boosters. These results collectively emphasise the importance of booster vaccines. The observation of waning protection indicates that in due course these may need to be repeated. Importantly, vaccine-mediated protection against severe disease is likely to be more durable than that against detected infection 49 . . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint We obtained nasopharyngeal swabs from 5 patients who were confirmed to be PCR-positive for infection with the SARS-CoV-2 Omicron variant. We attempted virus isolation in BHK-21 cells stably expressing the human ACE2 protein (BHK-hACE2) and VERO cells stably expressing ACE2 and TMPRSS2 (VAT 69 ). The infected cells were incubated at 37 o C and the cells monitored for signs of cytopathic effect (CPE) and the presence of viral progeny in the medium by RT-qPCR. While we observed no CPE in any of the infected cells, by RT-qPCR data at 5 days post-infection (dpi) we confirmed the presence of the virus derived from two of the five samples (referred from now on as 204 and 205) only in the medium of BHK-hACE2, but not VAT cells (Supp. Fig. S7A ). An aliquot of the clarified medium containing approximately 4x10 4 viral genomes of the P0 stocks of samples 204 and 205 was used to infect VAT, BHK-ACE2 and Calu-3 cells. Again, no CPE was observed in any of the infected cells but virus replication was confirmed in BHK-Ace2 and Calu-3 by RT-qPCR. Supernatants (termed P1) from infected Calu-3 cells at 3 dpi were collected and virus titrated by both focus forming assay and RT-qPCR. We found that the virus reached more than 100-fold higher titres in Calu-3 cells compared to BHK-hACE2 (Supp. Fig. S7B ). Further passage of sample 205-derived P1 virus in both Calu-3 and Caco-2 yielded equivalent genome copy numbers in both cell lines (Supp. Fig. S7B ). We observed CPE at 3 dpi in both Calu-3 and Caco2 cells (not shown). The medium (termed P2) of infected Calu-3 and Caco2 cells was collected at 4 dpi, titrated and used in the experiments described below. Our data demonstrate that antigenic change in Omicron permits evasion of vaccine induced immunity, however, the constellation of spike mutations in Omicron suggest that functional change may also contribute to its rapid transmission (Fig.1A) . Therefore, we investigated the virological properties of live Omicron isolated from a patient sample. SARS-CoV-2 particles can achieve membrane fusion at the cell surface following proteolytic activation of spike by the plasma membrane protease TMPRSS2. This property also permits spike-mediated fusion of SARS-CoV-2 infected cells with adjacent cells resulting in syncytia 50 ; this feature has been associated with severe disease 51 . The SARS-CoV-2 Delta variant has been shown to exhibit enhanced fusion compared to the Alpha and Beta variants 52 . We used the split GFP cell-cell fusion system 53 to quantify virus-induced cell fusion by Omicron, Delta and first wave Wuhan D614G virus (Fig. 5A) . Cells expressing split GFP were infected with SARS-CoV-2 Wuhan-D614G, Delta or Omicron and the levels of the reconstituted GFP signal following cell-cell fusion was determined in real time (Fig. 5B) . In addition, infected cells were probed by indirect immunofluorescence assay to assess viral replication by the detection of the viral nucleocapsid protein (Fig. 5C) . The Delta variant exhibited the highest levels of cell fusion followed by Wuhan D614G. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint Interestingly, the Omicron variant failed to promote fusion. This failure was not due to lack of infection as immunofluorescent detection of nucleocapsid protein confirmed viral replication by Omicron, as well as the other two variants. By immunofluorescence, syncytia were clearly evident in Wuhan D614G and Delta-infected cells, consistent with other recent reports 25 . We next tested virus replication of Omicron, compared to Delta and Wuhan D614G in Calu-3, a human lung epithelial cell line. As shown in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint Entry of SARS-CoV-2, and related coronaviruses, can proceed via two routes 55 . Cell surface fusion following proteolysis by TMPRSS2, as described above (Route 1; Fig. 6A ), or fusion from the endosome after endocytosis and activation by the endosomal proteases Cathepsin B or L (Route 2; Fig. 6A ). The ability of SARS-CoV-2 to achieve cell surface fusion is dependent on its S1/S2 polybasic cleavage site; this is absent from most closely related sarbecoviruses, which are confined to endosomal fusion [56] [57] [58] . Given the reduced fusogenicity and replication kinetics of Omicron, we used HIV pseudotypes to evaluate entry route preference. We evaluated Wuhan D614G, Alpha, Delta and Omicron spike and as a control we included Pangolin CoV (Guangdong isolate) spike, which exhibits high affinity interactions with human ACE2 but lacks a polybasic cleavage site and, therefore, enters via the endosome only 59-62 . Calu-3 cells predominantly support cell surface (Route 1) fusion, owing to their high endogenous expression of TMPRSS2 57, 63 ; in these cells, Delta yielded the highest infection, being ~4 fold higher than Omicron (Fig. 6B) . Pangolin CoV infection was low, indicating that Calu-3 cells do not support robust endosomal entry. On the contrary, HEK only support endosomal entry and in these cells Pangolin CoV had high infection. Notably, Omicron also achieved high infection in HEK cells, producing ~10 fold greater signal than Delta. This suggests that Omicron, like Pangolin CoV, is optimised for endosomal entry. All pseudotypes exhibited robust infection in A549 ACE2 TMPRSS2, where both entry routes are available 64, 65 . Entry pathway preference was further investigated using protease inhibitors targeting either TMPRSS2 (Camostat) or cathepsins (E64d) 58 . In Calu-3 cells, all SARS-CoV-2 pseudotypes were inhibited by Camostat, whereas only Omicron exhibited E64d sensitivity, indicating that a component of infection occurs via endosomal entry (Fig. 6C) . In HEK cells all pseudotypes were inhibited by E64d, whereas Camostat was non-inhibitory; this confirms that only endosomal entry is available in these cells. Inhibitor treatment in A549 ACE2 TMPRSS2 provided the clearest evidence of altered entry by Omicron. D614G, Alpha and Delta were potently inhibited by Camostat, but not E64d. For Omicron, and Pangolin CoV, this pattern was completely reversed, suggesting a binary switch from cell surface to endosomal fusion; this conclusion was supported by titration of either inhibitor in A549 ACE2 TMPRSS2 cells (Fig. 6D) . These data indicate that, whilst Delta is optimised for fusion at the cell surface, Omicron preferentially achieves entry through endosomal fusion; this biological about-face may impact transmission, cellular tropism and pathogenesis. Moreover, this switch away from TMPRSS2-mediated activation offers a mechanistic explanation for reduced syncytia formation by Omicron infected cells. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint The Omicron variant represents a major change in biological function and antigenicity of SARS-CoV-2 virus. In this study, we demonstrate substantial immune escape of this variant with clear evidence of vaccine failure in dual vaccinated individuals and partial restoration of immunity following a third booster dose of mRNA vaccine. In addition, we demonstrate a shift in the SARS-CoV-2 entry pathway from cell surface fusion, triggered by TMPRSS2, to cathepsin-dependent fusion within the endosome. This fundamental biological shift may affect the pathogenesis and severity of disease and requires further evaluation in population-based studies. Using sera from double vaccine recipients, we found that Omicron is associated with a drop in neutralisation greater in magnitude than that reported in all other variants of concern (including Beta and Delta). Boosting enhanced neutralising responses to both Wu-Hu-1 and Omicron, particularly in recipients of ChAdOx1, but did not completely overcome the inherent immune escape properties of Omicron. Importantly, we did not assess the impact of vaccination on clinical severity of disease which is likely to be much higher than detection of infection. Protection against severe disease is longer lasting than prevention of infection. We also did not measure the impact of vaccination on T cell immunity which may be better preserved as only 14% of CD8+ and 28% of CD4+ epitopes are predicted to be affected by key Omicron mutations 17 . In order to evaluate the impact of reduced neutralisation responses in vaccine recipients, we next assessed vaccine effectiveness. The probability of infection with Omicron versus the preceding Delta variant was significantly higher in double vaccine recipients, in keeping with the neutralisation data. A third dose of mRNA vaccine substantially reduced the probability of infection but did not restore immunity fully. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint human airway epithelial cells for the original emergent SARS-CoV-2, and previous VOCs by permitting spike activation by the plasma membrane protease TMPRSS2, enabling rapid cell surface fusion 55 . In this study, we found that the Omicron variant has switched entry pathway to preferentially use endosomal fusion that is independent of TMPRSS2; a major change in the biological behaviour of the virus. This switching in the mechanism of fusion activation also manifests in reduced syncytia formation in infected cells, likely to reduce the cell-to-cell transmission characteristic of other variants. These properties have the potential to substantially change cellular tropism and pathogenesis of disease. Nonetheless, even a variant that is less virulent with a very high transmission rate may still present a substantial risk to older people and those with co-morbidities, especially those with immunosuppression. Moreover, our work demonstrates that SARS-CoV-2 exhibits high antigenic and functional plasticity; further fundamental shifts in transmission and disease should be anticipated. Calu-3 are human lung adenocarcinoma epithelial cells. Caco-2 are an immortalized cell line derived from human colorectal adenocarcinoma, primarily used as a model of the intestinal epithelial barrier. A549 cells, a human alveolar adenocarcinoma line, were modified to stably express human ACE-2 and TMPRSS2. Human embryonic kidney (HEK293T) cells were used in pseudotype production. Omicron SARS-CoV-2. All cell lines were maintained at 37°C and 5% CO 2 in DMEM supplemented with 10% foetal bovine serum (FBS), except for Calu-3 cells which were supplemented with 20% FBS. (GenBank NM_001371415.1) were produced as described previously 69 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. Cell imagines were acquired using EVOS Cell Imaging Systems (Thermo Fischer Scientific). Demographic data. Data for the EVADE study were available using the NHS Greater Glasgow and Clyde is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. We identified Omicron infections using 3 data streams: confirmed S gene target failure (SGTF), allele specific PCR, and Pango lineage assignments from the sequencing data. SGTF samples with Delta lineage assignments were assigned as Delta infections. Samples for which the sequencing date was more than two weeks away from the first positive PCR were removed from the analysis. We removed a small number of individuals who received ChAdOx1 as a third dose or had their third dose before the first of September 2021 on the assumption that the majority were part of the COV-BOOST clinical trial, the results of which are published elsewhere. We removed anyone with ambiguous vaccination status or whose brand was unknown due to data entry error. Vaccine Cohort Study (DOVE), a cross-sectional post-licensing cohort study to determine the immunogenicity of deployed COVID-19 vaccines against evolving SARS-CoV-2 variants. 308 adult volunteers aged at least 18 years and were recruited into the study 14 days or more after a second or third dose of vaccine. All participants gave written informed consent to take part in the study. The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint On the 27 th November 2021, the UK Health Security Agency detected 2 cases of Omicron in England, the following day 6 Scottish cases were detected by community (Pillar 2) sequencing. Over the next 10 days (to 8 th December 2021) a further 95 genome sequences were obtained. Due to the rapid spread of Omicron and low genetic diversity, the genome sequences are highly related with mean genetic divergence of 1 single nucleotide polymorphisms (SNPs) and maximum 7 SNPs. The phylogenetic relationship to Omicron sequences from other countries is consistent with multiple introductions associated with travel to South Africa followed by community transmissions within Scotland. Amongst the Scottish samples diverged from the tree backbone, there were a number identified that are genetically divergent, i.e., greater than 2 single nucleotide polymorphisms from the nearest Scottish sample ( Figure 1D ). Moreover, comparison to the wider international collection of Omicron samples revealed that they were more closely related to genomes from other countries than other Scottish samples. These samples therefore likely represent independent introductions to Scotland, but without more detailed epidemiological data, the number of introductions is unknown. Where there are indistinguishable samples in the phylogeny from Scotland and elsewhere in world, importation cannot be ruled out as a source of these samples in Scotland, rather than transmission from an established population circulating in Scotland. Within Scotland, cases are spread across 9 separate Health Boards and distributed throughout the phylogeny ( Figure 1D ). Basal Scottish genomes were sampled in 7 different Health Boards, most of them from NHS Greater Glasgow & Clyde (47%) and NHS Lanarkshire (25%). Notably, amongst these earliest samples are cases that were epidemiologically linked to early spreading events. All but one of these samples were found on this basal branch and are indistinguishable, and which is consistent with transmission at these events. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. Antibody responses were studied in three groups of individuals (n=24 per group) vaccinated with either BNT162b2, ChAdOx1 or mRNA-1273 by MSD-ECL assay. Responses were measured against full-length spike glycoprotein (Spike) from HCoVs 229E, OC43, NL63 and HKU1 and are expressed as MSD arbitrary units (AU/ml). The response to OC43 was significantly higher in BNT162b2 vaccinates than in ChAdOx1 vaccinates. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. Antibody responses were studied in four groups of individuals primed with two doses of either ChAdOx1 or BNT162b2, followed by a booster of BNT162b2 or mRNA-1273. Responses were measured by MSD-ECL assay against full-length spike glycoprotein (Spike) from HCoVs 229E, OC43, NL63 and HKU1 and are expressed as MSD arbitrary units (AU/ml). . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint Supplementary Figure S7 Isolation of Omicron in cell culture. A. Vero ACE2 TMPRSS2 (VAT) and BHK-hACE2 cells were inoculated with diluted clinical samples. Viral progeny was quantified in the medium 5 dpi by RT-qPCR. B. Aliquots of the medium from samples named 204 and 205 were used to generate a P1 in BHK-hACE2 and Calu-3 cells and, limited to sample 205, a P2 in Calu-3 and Caco2 cells. Viral stocks were quantified by RT-qPCR. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.03.21268111 doi: medRxiv preprint WHO SPRP 2021 Mid-term Report -WHO Strategic Action Against COVID 19 Reduced neutralisation of the Delta (B. 1.617. 2) SARS-CoV-2 variant of concern following vaccination AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets Selection analysis identifies significant mutational changes in Omicron that are likely to influence both antibody neutralization and Spike function (Part 1 of 2) -SARS-CoV-2 coronavirus -Virological Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy SARS-CoV-2 Omicron: reduction of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern SARS-CoV-2 T cell responses are expected to remain robust against Omicron Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial Evidence for antibody as a protective correlate for COVID-19 vaccines Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Generalized additive models: an introduction with R Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study Protection and waning of natural and hybrid COVID-19 immunity Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant A new cell-based assay to evaluate myogenesis in mouse myoblast C2C12 cells A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor SARS-CoV-2 entry into human airway organoids is serine proteasemediated and facilitated by the multibasic cleavage site Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses Structure and binding properties of Pangolin-CoV spike glycoprotein inform the evolution of SARS-CoV-2 Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites Characterisation of B. 1.1. 7 and Pangolin coronavirus spike provides insights on the evolutionary trajectory of SARS-CoV-2. bioRxiv Cell-type-resolved quantitative proteomics map of interferon response against SARS-CoV-2 The polybasic cleavage site in SARS-CoV-2 spike modulates viral sensitivity to type I interferon and IFITM2 Identification of required host factors for SARS-CoV-2 infection in human cells Severity of omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland Report 50 -Hospitalisation risk for Omicron cases in England | Faculty of Medicine | Imperial College London Evolution of enhanced innate immune evasion by SARS-CoV-2 SARS-CoV-2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2 Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo Dr Paul A Randell 38 Metadata curation, and Sequencing The authors would like to thank the participants of the DOVE study and Sister Therese McSorley and her nursing team at the NHS GG&C clinical research facility. The authors also thank Alison Hamilton, Laura Stirling and Charlie Mayor from the NHS GG&C SafeHaven team for their invaluable input in facilitating this study. We thank Paula Olmo for administrative support and Chris Robertson and Aziz